Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oakmark Fund William C. Nygren, Michael A. Nicolas, Robert F. Bierig | “Zimmer Biomet is a leading medical device company and a pure play in orthopedics. In our view, orthopedics is an attractive product category that should benefit from long-term tailwinds stemming from an aging population, greater activity levels among seniors and increased adoption of specialized robotics that improve surgical efficiency. In addition, market share within the space tends to be sticky, as physicians are typically trained to use leading brands like Zimmer Biomet, reinforcing longstanding brand loyalty. New management recently completed several multi-year initiatives that we think will streamline operations and reinvigorate product innovation. The market has yet to ascribe value to these improvements, providing the opportunity to initiate a position in a dominant, growing company at a discounted valuation to peers and the broader market. BSD Analysis: Zimmer Biomet is emerging from a long operational slog with a sharper product portfolio and cleaner execution. Orthopedics has secular tailwinds — aging populations, rising joint replacements, and a return of elective procedures. Margins are recovering as supply chain issues ease. Surgeon loyalty and hospital contracts remain durable moats. Investors have priced ZBH like a perpetual laggard, but the turnaround is showing real traction. As procedure volumes normalize globally, Zimmer's earnings power should look materially stronger. This is a classic medtech recovery play with catalysts lining up.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
